Pentadeca Arginate (PDA)
Also known as: PDA, pentadecapeptide arginate, BPC-157 arginate
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A newer compound structurally related to BPC-157, marketed heavily for tissue recovery — but with a notably thin published evidence base.
What it is & how it works
What it is
Pentadeca Arginate, usually shortened to PDA, is a newer compound described as a modified, arginate form related to BPC-157. It has been marketed aggressively in the recovery space.
How it is thought to work
The proposed mechanism borrows directly from BPC-157 — effects on angiogenesis, growth factors and tissue repair. Importantly, this is analogy, not a body of research on PDA itself.
The evidence and the caveat
This is one of the thinnest evidence bases in this encyclopedia, and we’d rather say so plainly: independent published research on PDA specifically is essentially absent. Most of the enthusiasm is marketing that leans on BPC-157’s reputation. Treat strong claims — about benefits or safety — with appropriate skepticism.
What it's discussed & studied for
- Tissue and soft-tissue recovery (marketing-driven)
- Inflammation and healing discussion (anecdotal)
Discussion of a use is not a claim that it works or is approved.
Research status
Largely a market/community phenomenon. Independent published human research is essentially absent; most claims trace to marketing and analogy with BPC-157.
Evidence quality
Among the weakest evidence bases in this encyclopedia. Interest is driven by marketing and its relationship to BPC-157, not by direct trials of PDA itself.
Dosing discussion
No validated protocol or published dosing exists. Anything circulating is extrapolated from BPC-157 practice and vendor materials.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
There is little to no independent safety data on PDA specifically. Treat confident safety claims skeptically — they are not backed by a real human evidence base.
Sourcing literacy
A heavily marketed research-market compound with minimal independent characterization. Identity, purity and even consistent definition vary between sources.
Selected literature
FAQ
Is Pentadeca Arginate the same as BPC-157?
It's marketed as a related, modified form, but it is not identical, and unlike BPC-157 it has almost no published research of its own.
Is there real evidence for PDA?
Very little. Most of the interest is marketing-driven and borrows credibility from BPC-157 rather than from direct studies of PDA.